�we are glad that, at last, the commission is taking serious steps to fight air pollution before the court of justice,� clientearth lawyer ugo taddei said in a press release..

.

.

eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said....-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018..

"there may be subtle differences (between animals and humans) that we don't know about," klein said..

source: xinhua | 2018-05-18 02:09:13 | editor: chengcheng

.